• Boehringer Ingelheim Acquires AMAL Therapeutics americanpharmaceuticalreview
    July 16, 2019
    Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and ...
PharmaSources Customer Service